To The Moon

图片

In the past few years, $Novo-Nordisk A/S(NVO)$ has been on a roll in the capital markets, with its diabetes drug Ozempic and weight-loss drug Wegovy igniting a frenzy. Its stock price has skyrocketed 270% in the past three years.

But now, the weight-loss stock is about to get even hotter with the arrival of its "third fire" - the oral weight-loss drug amycretin.

Recent trial results for amycretin released by Novo Nordisk show that this experimental drug is even more effective than Ozempic and Wegovy in terms of weight loss. As a result, the company is considering skipping straight to phase three trials.

If this plan pans out, it'll speed up the development and launch of amycretin. But let's be realistic - even if it does work, this weight-loss drug is still going to take years to get approved and hit the market.

If amycretin continues to progress smoothly in trials and successfully hits the shelves, it'll definitely give Novo Nordisk even more long-term growth potential.

The results for amycretin are definitely encouraging, but we're still left wondering: Will the subsequent trials be successful? And how much will this drug boost the company's long-term performance once it's on the market?

In addition, the weight-loss drug market is a fiercely competitive one, with Novo Nordisk facing stiff competition from rivals like $Eli Lilly(LLY)$ recently approved weight-loss drug Zepbound.

But hey, with Ozempic and Wegovy already in their arsenal, Novo Nordisk's market position is still solid. It remains the top pick for investors looking to cash in on the weight-loss drug craze.